Oncology Drug Reference Sheet: Alpelisib
When used in combination with fulvestrant, alpelisib (Piqray®) produced complete or partial responses in 29% of patients with PIK3CA-altered, estrogen receptor-positive advanced breast cancer in clinical trials. The U.S. Food and Drug Administration approved it for use in 2019.
Health Care Reunites a Divided Nation
The November 2020 presidential election saw a historic turnout at the polls. Before election day, more than 99 million of the 240 million registered American voters had already cast their ballots, and some predicted that as many as 155 million voters would exercise their constitutional franchise to make their voices heard, a record 65% of the electorate. The distinct differences between the two major presidential candidates indicated that people were engaged and took to heart the grand idea of participatory democracy.
Genomics May Trick PARP Inhibitors to Treat More Cancers
Turning on the body’s inflammasome with epigenetic therapy may improve the efficacy of PARP inhibitors across multiple tumor types, possibly expanding the therapy’s application to new cancers, researchers reported in Proceedings of the National Academy of Sciences.
Meet Your ONS Leader: Barbara Holmes Gobel
Get to know Barbara Holmes Gobel, MS, RN, AOCN®, FAAN, ONS Leadership Development Committee member from 2020–2023. Barb is the associate chief nurse executive, director of professional practice and development, and Magnet program director for Northwestern Memorial Hospital in Chicago, IL.
FDA Approves Selinexor for Relapsed or Refectory Multiple Myeloma
On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved selinexor (Xpovio®) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refectory multiple myeloma who have received at least one prior therapy.
FDA Approves Osimertinib as Adjuvant Therapy for NSCLC With EGFR Mutations
On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso®) as adjuvant therapy after tumor resection for patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test.
- Read more about FDA Approves Osimertinib as Adjuvant Therapy for NSCLC With EGFR Mutations
- Add new comment
FDA Approves Relugolix for Advanced Prostate Cancer
On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved the first oral gonadotropin-releasing hormone receptor antagonist, relugolix, (Orgovyx™) for adult patients with advanced prostate cancer.
How to Establish a More Compassionate Workplace
A career of more than 40 years provides experiences and insight that can help nurses prioritize self-care, be more resilient, and stay positive during stressful times. During an on-demand session for the inaugural ONS BridgeTM virtual conference in October 2020, Susan Childress, MN, RN, former director of nursing at Huntsman Cancer Institute (HCI) in Salt Lake City, UT, and recipient of the 2020 Mara Mogensen Flaherty Memorial Lectureship, offered advice for oncology nurses in maintaining compassionate care and resiliency in practice.
FDA Approves Margetuximab-cmkb for Metastatic HER2-Positive Breast Cancer
On December 16, 2020, the U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb (Margenza™) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who previously received two or more anti-HER2 regimens, at least one of which was for metastatic disease.
- Read more about FDA Approves Margetuximab-cmkb for Metastatic HER2-Positive Breast Cancer
- Add new comment
The Case of Concurrent Therapy Concerns
Sharon is a 60-year-old woman with metastatic breast cancer that was originally diagnosed in 2005 and treated with a mastectomy, deep inferior epigastric artery perforator flap reconstruction, chemotherapy, post mastectomy radiation, and five years of tamoxifen. Three months ago, her breast cancer recurred, and staging scans demonstrated metastatic disease in the lungs, left axilla, liver, and left iliac bone. A biopsy of the left iliac bone was ER positive, PR negative, and HER2 negative. Sharon began treatment with radiation to the painful left hip and letrozole, with the plan to start palbociclib once radiation was completed.